Haloperidol versus risperidone: A comparison of beneficial effect on cognitive function of patients with chronic schizophrenia

Iranian Journal of Psychiatry and Behavioral Sciences

Volumn 2, Issue 1, 2008, Pages 14-20

  Abdolahian, Ebrahim ^a   Mohareri, Fatemeh ^a   Bordbar, Mohammad Reza Fayyazi ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cognition; Haloperidole; Risperidone; Schizophrenia; WCST

Indexed keywords

HALOPERIDOL; RISPERIDONE;

ADULT; AGED; AGITATION; ANXIETY; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PARKINSONISM; POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; TARDIVE DYSKINESIA; WISCONSIN CARD SORTING TEST;

EID: 77954991069     PISSN: 17358639     EISSN: 17359287     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Davies LM, Drummond MF. Economics and schizophrenia: the real cost. Br J Psychiatry 1994; 25 supp l: 18-21.
2. Knapp M. Cost of schizophrenia. Br J Psychiatry 1997; 171: 509-18.
3. Kaplan HI, Sadock BJ, editors. Synopsis of Psychiatry, Behavioral Sciences/ Clinical Psychiatry. Philadelphia: Lippincott Williams and Wilkins; 1998. p. 457-89.
4. Buchanan RW, Carpenter WT. Concept of Schizophrenia. In: Sadock BJ, MD and Sadock VA , MD editors. Kaplan and Sadock's Comprehensive textbook of psychiatry. Philadelphia: Lippincott Williams and Wilkins; 2005. Vol. 2. p. 1329-45.
5. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin pKi values. J Pharmacol Exp Ther 1989; 251: 238-46.
6. Nyberg S, Nordstrm A-L, Halldin C, Farde L. Positron emission tomography studies on D2 dopamine receptor occupancy and anti-psychotic drug plasma levels in man. Int Clin Psychopharmacology 1995; 10 suppl 3: 81-5.
7. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998; 18(2): 63-101.
8. Kasper S, Tauscher J, Kufferle B, Barnas C, Hesselmann B, Asenbaum S, et al. Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol: a 123 I-IBZM SPECT study. Psychopharmacology 1998; 136: 367-73.
9. Kasper S. How much do novel antipsychotics benefit the patients? Int Clin Psychopharmacol 1998; 13 Suppl 3: S71-7.
10. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, et al. A Canadian multi center placebo controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J. Clin. Psychopharmacol 1993; 13: 25-40.
11. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151: 825-35.
12. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995; 166: 712-26.
13. Heck AH, Haffmans PM, de Groot IW, Hoencamp E.Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double blind, multi center trial. Shizophrenia Research 2000; 46: 97-105.
14. Hunter RH, Joy CB, Kennedy E, Gilbody SM, Song F. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev 2003; (2): CD000440.
15. Dossenbach M, Erol A, el Mahfoud KM, Shaheen MO, Sunbol MM, Boland J, et al. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. J Clin Psychiatry 2004; 65(3):312-21.
16. Yen YC, Lung FW, Chong MY. Adverse effects of risperidone and haloperidol treatment in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28(2): 285-90.
17. de Sena EP, Santos-Jesus R, Miranda-Scippa A, Quarantini LC, Oliveira IR. [Relapse in patients with schizophrenia: a comparison between risperidone and haloperidol.] Rev Bras Psiquiatr 2003; 25(4): 220-3. Portuguese.
18. Marder SR, Glynn SM, Wirshing WC, Wirshing DA, Ross D, Widmark C, et al. Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. Am J Psychiatry 2003; 160(8):1405-12.
19. Gothelf D, Apter A, Reidman J, Brand- Gothelf A, Bloch Y, Gal G, et al. Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. J Neural Transm 2003; 110(5): 545-60.
20. Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, et al. Risperidone and haloperidol in first-episode psychosis:a long-term randomized trial. Am J Psychiatry 2005; 162(5): 947-53.
21. Crespo-Facorro B, Perez-Iglesias R, Ramirez-Bonilla M, Martinez-Garcia O, Llorca J, Luis Vazquez-Barquero J. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. J Clin Psychiatry 2006; 67(10): 1511-21.
22. McCue RE, Waheed R, Urcuyo L, Orendain G, Joseph MD, Charles R, et al. Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. Br J Psychiatry 2006; 189: 433-40.
23. Glick ID, Shkedy Z, Schreiner A. Differential early onset of therapeutic response with risperidone vs. conventional antipsychotics in patients with chronic schizophrenia. Int Clin Psychopharmacol 2006; 21(5): 261-6.
24. Scher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry 2006; 6: 8.
25. Gareri P, De FP, Stilo M, Ferreri G, De SG. Conventional and atypical antipsychotics in the elderly: a review. Clin Drug Investig 2003; 23(5): 287-322.
26. Stip E. [Cognition, schizophrenia and the effect of antipsychotics.] Encephale 2006; 32(3 Pt 1): 341-50. French.
27. Fakra E, Salgado-Pineda P, Besnier N, Azorin JM, Blin O. Risperidone versus haloperidol for facial affect recognition in schizophrenia: Findings from a randomized study.World J Biol Psychiatry 2007; 10:1-10.
28. Lee SM, Chou YH, Li MH, Wan FJ, Yen MH. Effects of antipsychotics on cognitive performance in drug-naive schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31(5):1101-7.
29. Terry AV Jr., Gearhart DA, Warner SE, Zhang G, Bartlett MG, Middlemore ML, et al. Oral haloperidol or risperidone treatment in rats: temporal effects on nerve growth factor receptors, cholinergic neurons, and memory performance. Neuroscience 2007; 146(3): 1316-32.
30. Harvey PD, Rabinowitz J, Eerdekens M, Davidson M. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry 2005; 162(10): 1888-95.
31. Keefe RS, Young CA, Rock SL, Purdon SE, Gold JM, Breier A. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone,and haloperidol in schizophrenia. Schizophr Res 2006; 81(1): 1-15.
32. Daneshmand R, Mazinani R, Fadai F. [The effect of risperidone on cognitive symptoms of schizophrenia: a comparison with haloperidol.] Journal of Mazandaran University of Medical Sciences 2007; 17(59): 1-10. Persian.